InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator in... InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -3.30578512397 | 1.21 | 1.27 | 1.1319 | 222779 | 1.20370548 | CS |
4 | -0.8 | -40.6091370558 | 1.97 | 1.9808 | 1.1319 | 409253 | 1.43934819 | CS |
12 | -1.32 | -53.0120481928 | 2.49 | 2.77 | 1.1319 | 364442 | 1.93259345 | CS |
26 | -0.27 | -18.75 | 1.44 | 2.815 | 1.1319 | 292551 | 2.00382935 | CS |
52 | -0.38 | -24.5161290323 | 1.55 | 2.815 | 1.1319 | 215069 | 1.83654349 | CS |
156 | -1.24 | -51.4522821577 | 2.41 | 7.2499 | 0.7762 | 424455 | 3.66941823 | CS |
260 | -1.48 | -55.8490566038 | 2.65 | 9.7 | 0.7762 | 582840 | 4.17862802 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions